# OnCo record nct07565285 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07565285/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07565285", "NCT07565285" ;
  schema:name "The Efficacy and Safety of PRTX007-003 Combined With Pembrolizumab in Resectable Stage III Melanoma"@en ;
  schema:alternateName "INFLECTION-003"@en ;
  schema:description "A phase 2 trial of Pembrolizumab in melanoma, run by Primmune Therapeutics, Inc., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07565285/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07565285> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2026-07-01" ;
  onco:cancers <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/stage-iii-melanoma/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/prtx007/> ;
  onco:companies <https://onco.cc/companies/primmune-therapeutics/> .